Journal of Clinical Lipidology
Scope & Guideline
Elevating cardiovascular health through lipid research.
Introduction
Aims and Scopes
- Lipid Disorders and Genetic Factors:
The journal emphasizes research on genetic predispositions to lipid disorders, particularly familial hypercholesterolemia, dyslipidemia, and related metabolic syndromes. This includes studies on genetic mutations, their phenotypic expressions, and implications for diagnostics and treatment. - Clinical Management of Lipid Disorders:
A significant focus is placed on the clinical management of patients with lipid disorders, including the effectiveness of various pharmacotherapies, dietary interventions, and lifestyle modifications aimed at reducing cardiovascular risk. - Innovative Therapeutic Approaches:
The journal highlights novel therapeutic strategies, such as PCSK9 inhibitors, antisense oligonucleotides, and other lipid-lowering agents, along with their clinical outcomes and safety profiles. - Epidemiology and Public Health:
Research addressing the epidemiology of lipid disorders, their prevalence in different populations, and the impact of public health initiatives on lipid management and cardiovascular disease prevention is a key area of interest. - Implementation Science in Lipidology:
The journal explores the application of implementation science to improve lipid screening, diagnosis, and management protocols within clinical settings, enhancing patient outcomes and healthcare delivery.
Trending and Emerging
- Familial Hypercholesterolemia and Genetic Testing:
Research on familial hypercholesterolemia, including genetic testing and screening guidelines, has surged. This reflects a growing recognition of the importance of early diagnosis and management of genetically predisposed individuals to prevent cardiovascular events. - Lipoprotein(a) and Cardiovascular Risk:
There is an increasing focus on lipoprotein(a) as an independent risk factor for cardiovascular disease, with studies investigating its measurement, clinical implications, and management strategies, indicating a significant shift in understanding lipid-related risks. - Implementation of Novel Therapies:
The journal is trending towards studies evaluating the real-world effectiveness and safety of novel lipid-lowering therapies, particularly PCSK9 inhibitors and RNA-based treatments, as they become more integrated into clinical practice. - Diversity and Disparities in Lipid Management:
Emerging themes include the examination of disparities in access to lipid management therapies across different populations, including racial, ethnic, and socioeconomic factors that influence treatment outcomes. - Lipidomics and Precision Medicine:
Research integrating lipidomics into clinical practice is gaining traction, focusing on personalized approaches to lipid management based on individual lipid profiles and genetic backgrounds, reflecting a move towards precision medicine in lipidology.
Declining or Waning
- Traditional Dietary Approaches:
There is a noticeable decline in studies focusing on traditional dietary approaches to managing dyslipidemia, such as low-fat diets, as newer research emphasizes the role of specific dietary components like omega-3 fatty acids and the Mediterranean diet. - Basic Lipid Biochemistry Studies:
Research centered solely on basic lipid biochemistry without clinical implications is becoming less prevalent. The journal is now favoring studies that translate biochemical findings into clinical practice or patient outcomes. - Historical Case Studies:
The frequency of historical case studies documenting rare lipid disorders is decreasing, possibly due to a shift towards more contemporary clinical trials and cohort studies that provide more relevant data for current practices. - Single-Center Studies:
There is a waning interest in single-center studies that do not incorporate broader epidemiological data. The journal is increasingly prioritizing multi-center or population-based studies that provide more comprehensive insights. - Non-Pharmacological Interventions:
Research focusing on non-pharmacological interventions alone, such as exercise or lifestyle changes without pharmacotherapy, appears to be less frequent, as there is a stronger emphasis on integrated approaches combining medication and lifestyle modifications.
Similar Journals
Journal of Diabetology
Driving progress in diabetes research and treatment.The Journal of Diabetology, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Since its inception in 2010, this Open Access journal has provided researchers and healthcare professionals with a wealth of knowledge through rigorous peer-reviewed articles that cover clinical research, epidemiology, and innovative treatment strategies. With an E-ISSN of 2078-7685 and a commitment to disseminating high-quality scientific work, the journal plays a pivotal role in contributing to the global discourse on diabetes care and prevention. Its dedication to accessibility enhances its impact on both established scholars and emerging researchers seeking to make meaningful contributions in the field. By fostering a collaborative environment, the Journal of Diabetology aims to bridge the gap between research and practical implementation, ultimately improving outcomes for individuals affected by diabetes.
Clinical Nutrition ESPEN
Advancing the Science of Nutrition for Better HealthClinical Nutrition ESPEN is a distinguished journal published by ELSEVIER, focusing on the critical intersection of clinical nutrition and metabolic health. With an ISSN of 2405-4577, this journal serves as an essential resource for researchers, practitioners, and students in the fields of Endocrinology, Diabetes and Metabolism as well as Nutrition and Dietetics. Operating out of the United Kingdom, it has garnered a respectable Q2 ranking in both categories for 2023, indicating its significant impact and relevance in the field. Although it does not follow an open access model, the journal offers valuable insights into contemporary nutrition research, clinical practices, and dietary interventions, making it a vital tool for those committed to improving patient outcomes through nutritional science. In its evolving journey, covering work from 2015 to 2024, Clinical Nutrition ESPEN continues to shape the dialogue in nutrition research, addressing pressing health challenges and fostering innovation in dietetic practice.
PROSTAGLANDINS & OTHER LIPID MEDIATORS
Connecting Disciplines through Lipid SciencePROSTAGLANDINS & OTHER LIPID MEDIATORS, published by Elsevier Science Inc, is a leading journal dedicated to the advancements in the field of lipid mediators, with a specific focus on prostaglandins and other bioactive lipids. This journal, indexed under ISSN 1098-8823 and E-ISSN 2212-196X, serves as a crucial platform for researchers and professionals to disseminate significant findings that span multiple disciplines, including Biochemistry, Cell Biology, Pharmacology, and Physiology. In the 2023 category quartiles, it has achieved commendable positions such as Q2 in Biochemistry and Q2 in Physiology, underscoring its importance and influence in these domains. Although it is not an open-access journal, it provides robust access options, enhancing the visibility of vital research. With its establishment in 1996, the journal continues its commitment to fostering innovative research until 2024, making it an essential resource for those involved in the dynamic realms of lipid biology and medical research.
EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY
Elevating the standards of lipid science and technology.EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, published by WILEY, is a reputable academic journal dedicated to advancing the field of lipid science and technology. With an ISSN of 1438-7697 and E-ISSN 1438-9312, this journal serves as a critical resource for researchers, professionals, and students interested in the bioengineering, industrial applications, and nutritional science of lipids. Covering a broad spectrum from biochemistry to food science, it holds distinguished rankings across multiple categories, including Q2 in Chemistry and Food Science, and Q3 in Biotechnology, showcasing its significance in the interdisciplinary study of lipids. The journal welcomes Open Access options, fostering the dissemination of knowledge and innovation in lipid research. With converged years extending from 2000 to 2024, this journal remains at the forefront of lipid-related research, encouraging scholarly contributions that push the boundaries of science and technology.
LIPIDS
Shaping the future of lipid research with every publication.LIPIDS is a renowned peer-reviewed journal published by Wiley, dedicated to the field of lipid research, encompassing biochemistry, molecular biology, and organic chemistry. With its roots dating back to 1966 and a commitment to advancing knowledge until 2024, this journal serves as a vital platform for sharing significant findings in lipid biochemistry and its applications in health and disease. Although it currently does not offer Open Access options, it maintains a respectable standing with a Q3 ranking in Biochemistry and Organic Chemistry, and a Q4 ranking in Cell Biology based on the 2023 category quartiles. Additionally, its Scopus rankings reflect a solid position within the organic chemistry and biochemistry subfields. Published from Germany, LIPIDS caters to researchers, professionals, and students eager to explore the roles of lipids in biological processes and innovatory applications in various scientific disciplines.
CURRENT OPINION IN LIPIDOLOGY
Pioneering critical discussions in lipid research.Current Opinion in Lipidology is a premier journal published by Lippincott Williams & Wilkins, offering critical insights into the ever-evolving landscape of lipid research. With an impressive convergence spanning from 1990 to 2024, this journal serves as an essential platform for researchers, clinicians, and professionals dedicated to the study of lipids in relation to cardiovascular health, endocrinology, and metabolism. The journal currently holds a distinguished Q1 ranking in Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, and Nutrition and Dietetics, showcasing its significant impact in these fields. Additionally, it ranks in the Q2 quartile for Cell Biology and Molecular Biology, underlining its comprehensive approach to lipidology. Though not open access, the content is rich with cutting-edge reviews, clinical studies, and expert opinions that aim to advance knowledge and practice in lipid metabolism, making it a valuable resource for anyone seeking to stay abreast of the latest developments in lipid research.
DIABETES OBESITY & METABOLISM
Delivering cutting-edge research for a healthier future.DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.
Current Opinion in Endocrinology Diabetes and Obesity
Advancing Knowledge in Endocrinology, Diabetes, and ObesityCurrent Opinion in Endocrinology, Diabetes and Obesity, published by LIPPINCOTT WILLIAMS & WILKINS, offers a critical analysis of the latest advancements and trends in the fields of endocrinology, diabetes, and obesity. With an ISSN of 1752-296X and an E-ISSN of 1752-2978, this esteemed journal provides an authoritative platform for researchers, clinicians, and healthcare professionals to stay updated on emerging research and clinical practices. Renowned for its impactful contributions, the journal holds notable rankings, including Q2 in Endocrinology and Diabetes & Metabolism, as well as a commendable Q1 in Internal Medicine, reflecting its significance in the academic community. Although currently not an open access publication, articles published from 2007 to 2024 continually enrich the discourse on pressing health issues related to endocrinology and metabolic disorders. By fostering a comprehensive understanding of the complexities within these interconnected fields, it serves as an essential resource for any professional or student engaged in health science research.
Metabolic Syndrome and Related Disorders
Elevating Understanding of Chronic Disease InteractionsMetabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.
Current Vascular Pharmacology
Shaping the Future of Cardiovascular Pharmacological ResearchCurrent Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.